# Strongbridge Biopharma plc

Strongbridge Biopharma plc is a company headquartered in Trevose, PA, United States.

## Company overview

- **Legal name:** Strongbridge Biopharma plc
- **Former names in filing history:** Cortendo AB (2015-02-25 to 2015-08-28)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Trevose, PA, United States
- **Incorporated in:** Ireland
- **SEC CIK:** 0001634432

## About

Strongbridge Biopharma plc is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001634432, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2021-03-03, it reported annual revenue of USD 30,731,000; net income of USD -45,075,000; total assets of USD 121,100,000 for the fiscal period ended 2020-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2020 (period ended 2020-12-31)

- **Revenue:** $30.7M (USD 30,731,000)
- **Net income:** -$45.1M (USD -45,075,000)
- **Total assets:** $121.1M (USD 121,100,000)
- **Cash and equivalents:** $87.5M (USD 87,522,000)
- **Operating cash flow:** -$38.1M (USD -38,134,000)

### FY2019 (period ended 2019-12-31)

- **Revenue:** $21.7M (USD 21,712,000)
- **Net income:** -$49.5M (USD -49,451,000)
- **Total assets:** $117.6M (USD 117,638,000)
- **Cash and equivalents:** $57.0M (USD 57,032,000)
- **Operating cash flow:** -$44.8M (USD -44,784,000)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $18.0M (USD 18,027,000)
- **Net income:** $31.9M (USD 31,851,000)
- **Total assets:** $170.3M (USD 170,285,000)
- **Cash and equivalents:** $122.5M (USD 122,490,000)
- **Operating cash flow:** -$84.6M (USD -84,576,000)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $7.0M (USD 7,046,000)
- **Net income:** -$113.5M (USD -113,483,000)
- **Total assets:** $103.9M (USD 103,925,000)
- **Cash and equivalents:** $57.5M (USD 57,510,000)
- **Operating cash flow:** -$45.3M (USD -45,336,000)

## Recent SEC filings

- Form 8-K — filed 2021-10-05 — period 2021-10-05 — FORM 8-K
- Form 8-K — filed 2021-09-08 — period 2021-09-08 — FORM 8-K
- Form 8-K — filed 2021-08-30 — period 2021-08-30 — FORM 8-K
- Form 10-Q — filed 2021-08-05 — period 2021-06-30 — 10-Q
- Form 8-K — filed 2021-08-05 — period 2021-08-05 — 8-K
- Form 8-K — filed 2021-07-26 — period 2021-07-23 — 8-K
- Form SC 13G — filed 2021-07-09
- Form 8-K — filed 2021-07-07 — period 2021-07-02 — FORM 8-K
- Form 8-K — filed 2021-05-24 — period 2021-05-24 — 8-K
- Form 8-K — filed 2021-05-14 — period 2021-05-13 — 8-K
- Form 8-K — filed 2021-05-13 — period 2021-05-13 — 8-K
- Form 8-K — filed 2021-05-12 — period 2021-05-12 — 8-K

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/strongbridge-biopharma-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology